Frontline Checkpoint Inhibitor Monotherapy in NSCLC

Program Overview

This learner-friendly 15-minute infographic activity is augmented by physician videos in an interactive approach to key safety and efficacy data for frontline pembrolizumab, atezolizumab, and cemiplimab monotherapies in advanced non-small cell lung cancer (NSCLC).

Credit Expired

0.25 CE Credit(s)

Expires: June 24, 2022

Target Audience

Oncologists, pulmonologists, and other healthcare professionals involved in the treatment of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Evaluate the survival advantage versus chemotherapy for current and emerging frontline checkpoint inhibitor monotherapies in advanced nondriver non-small cell lung cancer (NSCLC) with high PD-L1 expression

Activity Faculty

Ahmet Sezer, MD

Professor, Medical Oncology
Başkent University
Adana, Turkey

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)
Yale Cancer Center
New Haven, CT

Brian Henick, MD

Assistant Professor of Medicine at CUIMC
Columbia University Irving Medical Center
New York, NY

Featured RMEI CE Activities

Climbing the Ladder to Optimal Outcomes in NTM-LD: Navigating a Clear Path from Diagnosis Thru Treatment

Halting the Vicious Vortex: Targeting Neutrophil Serine Protease Activation in Non-Cystic Fibrosis Bronchiectasis (NCFBE)

Tackling Treatment-Refractory and Drug-Resistant CMV in the Solid Organ Transplant Setting: A Care Team Forum®

Optimizing Biologic Therapy in Children with Moderate-to-Severe Atopic Dermatitis: A Care Team Forum®

Copyright © 2023. RMEI Medical Education, LLC. All rights reserved

Privacy | Terms of Use